The European Medicines Agency has recommended doctors not to prescribe rimonabant (also known as Acomplia), a well known anti-obesity drug.

According to EMEA, the drug can alarmingly increase the risk of serious psychiatric problems and even suicides.

As the patients who are at risk cannot be identified that’s why marketing of the drug must be suspended, the EMEA says.

Those patients who are using the drug must consult their doctor; however, they need not to stop using the drug instantly.

According to an estimate, almost 97,000 obese or overweight people in the UK have been prescribed rimonabant in conjunction with diet and exercise and around 20,000 are currently using the drug.

Read the rest of this entry